Based on our findings, antiviral treatment should be recommended for PLA2R positive HBV-MN patients once the diagnosis established while immunosuppressive therapy would be unnecessary unless impaired renal function or lethal complications associated with severe nephrotic syndrome. The gene discussed is PLA2R1; the disease is nephrotic syndrome.